- Report
- January 2026
- 197 Pages
Global
From €3419EUR$3,939USD£2,964GBP
- Report
- January 2026
- 184 Pages
Global
From €3419EUR$3,939USD£2,964GBP
- Report
- January 2026
- 383 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 413 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 194 Pages
Global
From €4297EUR$4,950USD£3,725GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1085EUR$1,250USD£941GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1302EUR$1,500USD£1,129GBP
- Report
- January 2026
- 185 Pages
Global
From €3906EUR$4,500USD£3,387GBP
- Report
- May 2025
- 180 Pages
Global
From €3906EUR$4,500USD£3,387GBP
- Report
- August 2025
- 150 Pages
Global
From €3471EUR$3,999USD£3,009GBP
- Report
- October 2025
- 150 Pages
Global
From €3342EUR$3,850USD£2,897GBP
€4210EUR$4,850USD£3,650GBP
- Report
- June 2025
- 190 Pages
Global
From €4336EUR$4,995USD£3,759GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2421EUR$2,789USD£2,099GBP
- Report
- May 2025
- 135 Pages
Global
From €4210EUR$4,850USD£3,650GBP
- Report
- April 2025
- 135 Pages
Global
From €4210EUR$4,850USD£3,650GBP
- Report
- September 2025
- 250 Pages
Global
From €3897EUR$4,490USD£3,379GBP
- Report
- November 2025
- 200 Pages
Global
From €6901EUR$7,950USD£5,983GBP
- Report
- July 2025
- 75 Pages
Global
From €15620EUR$17,995USD£13,542GBP
- Report
- March 2025
- 74 Pages
Global
From €15620EUR$17,995USD£13,542GBP
- Report
- August 2024
- 120 Pages
Global
From €5165EUR$5,950USD£4,478GBP

Uveitis is an inflammatory condition of the eye that can cause vision loss and other complications. Immune disorders drugs are used to treat uveitis and other immune-mediated diseases. These drugs are designed to reduce inflammation and suppress the immune system. Commonly used drugs include corticosteroids, immunosuppressants, and biologics. Corticosteroids are used to reduce inflammation and suppress the immune system, while immunosuppressants are used to reduce the activity of the immune system. Biologics are used to target specific parts of the immune system and reduce inflammation.
The uveitis drug market is a rapidly growing segment of the immune disorders drugs market. It is driven by the increasing prevalence of uveitis and other immune-mediated diseases, as well as the development of new drugs and treatments. Companies in the market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more